Welcome to our dedicated page for HOOKIPA Pharma news (Ticker: HOOK), a resource for investors and traders seeking the latest updates and insights on HOOKIPA Pharma stock.
HOOKIPA Pharma Inc. (symbol: HOOK) is a clinical-stage biopharmaceutical company dedicated to the development of immunotherapeutics aimed at preventing and treating infectious diseases and cancer. Leveraging its proprietary arenavirus platform, HOOKIPA has created VaxWave® and TheraT®, groundbreaking technologies that reprogram and stimulate the immune system.
VaxWave® is a replication-deficient viral vector, while TheraT® is an attenuated replicating vector. Both technologies are designed to induce strong pathogen-neutralizing antibodies and CD8+ T cells. Remarkably, these vectors can be administered repeatedly without losing efficacy. TheraT® has shown the ability to stimulate CD8+ T cell responses to tumor antigens, achieving frequencies and potencies comparable to or surpassing those seen in adoptive T cell therapy.
HOOKIPA's viral vectors are administered systemically and target dendritic cells in vivo, effectively activating the immune system. This capability is particularly beneficial in the field of immuno-oncology, where it allows for the systemic combating of both primary and metastatic solid tumors.
In recent achievements, HOOKIPA has successfully completed a Phase 1 clinical trial, demonstrating the potential and safety of its innovative approaches. The company continues to focus on advancing its pipeline, which includes the development of an arenavirus-based immunotherapy for KRAS mutant cancer and a neoadjuvant HPV16-specific immunotherapy combined with chemotherapy for HPV16-positive oropharyngeal cancer.
As of December 31, 2023, the company maintains a robust financial position. HOOKIPA remains committed to pioneering immune-based treatments that offer hope for patients with infectious diseases and cancer, positioning itself at the forefront of biopharmaceutical innovation.
HOOKIPA Pharma Inc. (NASDAQ: HOOK), a biopharmaceutical company specializing in immunotherapies, announced its participation in investor meetings at the Van Lanschot Kempen Life Sciences Conference in Amsterdam on April 25-26, 2023. This event highlights HOOKIPA's commitment to advancing its proprietary arenavirus platform aimed at fighting serious diseases.
HOOKIPA is focused on developing therapies that enhance T cell responses to combat various cancers, including Human Papillomavirus 16-positive cancers and prostate cancers. Additionally, the company collaborates with Roche on treatments for KRAS-mutated cancers and aims to create functional cures for HBV and HIV alongside Gilead.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced the granting of non-statutory options for 50,000 shares of Common Stock to a new employee. This decision, approved by the Compensation Committee, is in line with Nasdaq Listing Rule 5635(c)(4) as an inducement for the employee's acceptance of employment. The exercise price is set at $1.00 per share, with a ten-year term and a vesting schedule that includes 25% vesting on the one-year anniversary and the remainder vesting quarterly over three years. HOOKIPA is a biopharmaceutical company focusing on immunotherapies developed from its proprietary arenavirus platform, targeting various cancers and collaborating with Roche and Gilead for future treatments.
HOOKIPA Pharma reported financial results and corporate updates for 2022, highlighting substantial progress in developing immunotherapeutics. The company strengthened its cash position to $113.4 million as of December 31, 2022, with an additional $15.0 million from collaboration milestones in early 2023. HOOKIPA's lead candidate, HB-200, advanced to Phase 2 trials in head and neck cancers, while its prostate cancer program, HB-300, is open for enrollment. The KRAS program (HB-700) achieved its first milestone payment from Roche in February 2023. Revenue decreased to $14.2 million in 2022, down from $18.4 million in 2021, primarily due to lower reimbursements from the Gilead collaboration.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced the appointment of Terry Coelho to its Board of Directors effective April 3, 2023. With over 35 years of experience, including roles in finance and business development at CinCor Pharma and Novartis, Coelho is expected to strengthen HOOKIPA's leadership as it advances its immunotherapeutic pipeline targeting oncology and infectious diseases. CEO Joern Aldag emphasized her strategic insights will be valuable for the company’s ongoing clinical programs. HOOKIPA is known for its proprietary arenavirus platform aimed at developing novel therapeutics for serious diseases.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced plans to release its fourth quarter and full year 2022 financial results on March 15, 2023, before the market opens. The company will host a live conference call at 8:30 AM ET to discuss these results and provide a corporate update. HOOKIPA specializes in developing immunotherapeutics based on its proprietary arenavirus platform, targeting cancers and viral diseases such as HBV and HIV. The company collaborates with notable partners including Roche and Gilead. For access details, participants can find the webcast link on HOOKIPA's investor relations page.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) has announced a $10 million non-dilutive milestone payment from Roche for the development of HB-700, an immunotherapy for KRAS-mutated cancers. This payment marks the initiation of the HB-700 manufacturing process in preparation for a Phase 1 clinical trial. HOOKIPA plans to file an Investigational New Drug Application (IND) with the FDA in the first half of 2024. The collaboration allows HOOKIPA to pursue further milestones totaling approximately $930 million, plus royalties, for this and another undisclosed program.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) will participate in the virtual SVB Securities Global Biopharma Conference from February 14-16, 2023. The company plans to deliver a corporate presentation on February 14, 2023, at 10:00 AM EST. Interested parties can access the live webcast and archived replay through the Investors & Media section of HOOKIPA’s website.
HOOKIPA is focused on developing innovative immunotherapies utilizing its proprietary arenavirus platform. Their pipeline includes therapies targeting Human Papillomavirus 16-positive cancers and prostate cancers, along with collaborations with Roche and Gilead on cancer and viral infections.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced a $5 million non-dilutive milestone payment from Gilead Sciences under their collaboration agreement. This payment corresponds to the completion of a regulatory support package for a Phase 1 clinical trial of a hepatitis B therapeutic vaccine utilizing HOOKIPA's arenavirus platform. The trial is set to dose its first participant in 2023. HOOKIPA is eligible for additional milestone payments exceeding $190 million, alongside tiered royalties on net sales as it advances its innovative immunotherapy developments.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) has announced the promotion of Katia Schlienger, M.D., Ph.D., to Chief Medical Officer and the appointment of Malte Peters, M.D., to its Board of Directors, effective January 1, 2023. Dr. Schlienger has been integral to HOOKIPA’s clinical strategy in immuno-oncology since joining in 2021. Meanwhile, Dr. Peters, with extensive experience in oncology and infectious disease, is poised to enhance HOOKIPA’s pipeline development. This leadership change is expected to strengthen the company’s clinical programs aimed at treating head and neck and prostate cancers.
HOOKIPA Pharma (NASDAQ: HOOK) announced its participation in the virtual investor meetings and panel discussions at The JMP Securities Hematology and Oncology Summit on December 6-7, 2022. The company focuses on developing novel immunotherapies using its proprietary arenavirus platform, which aims to mobilize targeted T cells against serious diseases. HOOKIPA’s pipeline includes investigational treatments for Human Papillomavirus 16-positive cancers, prostate cancers, and collaborations with Roche and Gilead for KRAS-mutated cancers and functional cures for HBV and HIV, respectively.
FAQ
What is the current stock price of HOOKIPA Pharma (HOOK)?
What is the market cap of HOOKIPA Pharma (HOOK)?
What does HOOKIPA Pharma Inc. specialize in?
What are VaxWave® and TheraT®?
How do the arenavirus technologies work?
What recent achievements has HOOKIPA made?
How are HOOKIPA's viral vectors administered?
What is the financial condition of the company?
What is the significance of TheraT® in cancer treatment?
Who can be contacted for investor relations?
What are the upcoming projects for HOOKIPA?
What makes HOOKIPA's technologies unique?
